This is part of the response I received from the FDA when I asked when the Regeneron Monoclonal Antibody cocktail will be available for use as a preventative in people who are immunocompromised such as with CLL. I have just included the information for the request of expanded use and not their entire response as it was very long. Thank you to the member who provided the information of sending questions to the FDA. It worked. It is good information.
Here is what they said:
REGEN-COV is not authorized for pre-exposure prophylaxis to prevent COVID-19 before being exposed to the SARS-CoV-2 virus -- only after exposure to the virus. If your physician feels that you are a candidate for pre-exposure prophylaxis, please ask your physician to reach out to FDA to request expanded access. Sometimes called “compassionate use”, expanded access is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.
You may provide this information to your physician in case he/she is unfamiliar with the process:
Expanded Access | FDA
Expanded Access | Information for Physicians | FDA
If you or your physician would like to speak to our staff about the process, please feel free to reach out to us at 301-796-3400.
Best Regards
HT
Pharmacist
Division of Drug Information
Center for Drug Evaluation and Research
Tel: 855-543-DRUG (855-543-3784)